SCHEMBL2800930

SCHEMBL2800930

CS(=O)(=O)NC(=O)c1cnn2c(NCc3ccccc3)c(C(=O)N3CCC4(C=Cc5ccccc54)CC3)cnc12

nearest known ligand 0.44

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MCHR2 Q969V1 3/20 0.39
FFAR1 O14842 2/20 0.38
CCR2 P41597 2/20 0.36
NPC1L1 Q9UHC9 2/20 0.36
SCD O00767 1/20 0.35
HSD11B1 P28845 1/20 0.35
OXTR P30559 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2801253 0.91 FFAR1 (0.40) MCHR2FFAR1CCR2NPC1L1SCD
SCHEMBL2801036 0.87 CCR2 (0.38) CCR2
SCHEMBL2803320 0.86 FFAR1 (0.39) MCHR2FFAR1CCR2NPC1L1SCD
SCHEMBL2799969 0.86 ALDH1A1 (0.34)
SCHEMBL2802821 0.86 ALDH1A1 (0.34)
SCHEMBL2801079 0.86 MCHR2 (0.38) MCHR2FFAR1NPC1L1HSD11B1OXTR
SCHEMBL2803834 0.84 RBP4 (0.40)
SCHEMBL2803842 0.84 SCD5 (0.36)
SCHEMBL2803194 0.84 AVPR1A (0.45) OXTR
SCHEMBL2804011 0.84 NPY5R (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 MCHR2 4007/4885FFAR1 4453/4885CCR2 4730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.